Linical Co., Ltd.

Equities

2183

JP3974530002

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-31 am EDT			5-day change	1st Jan Change
399 ^JPY	+2.84%		+1.01%	-24.72%

May. 15	Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 12, 2024; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2025	CI
May. 15	Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025	CI

Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025

May 15, 2024 at 03:00 am EDT

Linical Co., Ltd. provided forecast of consolidated financial result for the year ending March 31, 2025. For the period, the company expected Net sales of JPY 12,669 million, Operating income of JPY 1,009 million, Profit attributable to owners of parent of JPY 697 million, and Net income per share of JPY 30.86.

Latest news about Linical Co., Ltd.

Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 12, 2024; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2025	May. 15	CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025	May. 15	CI
Linical Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	Apr. 12	CI
Linical Cuts Revenue, Earnings Forecast on Lower-Than-Expected Sales, Extraordinary Losses	Feb. 21	MT
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024	Feb. 14	CI
Linical Seeks Listing on Standard Market Following Revised Tokyo Stock Exchange Rules	23-09-26	MT
Linical Co., Ltd. Provides Dividend Forecast for the Year Ending March 31, 2024	23-08-14	CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024	23-08-14	CI
Linical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-15	CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024	23-05-15	CI
Linical Co., Ltd. Provides Year Ending Dividend Forecast for the Year Ending March 31, 2024	23-05-15	CI
Linical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023	23-05-15	CI
Linical Co., Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2023	23-02-14	CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-02-14	CI
Linical Co., Ltd. Provides Earnings Guidance for the Year Ending March 2023	22-12-27	CI
Linical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2023	22-12-27	CI
Science 37 Holdings, Linical Americas to Deploy Decentralized Clinical Trial Services	22-11-17	MT
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-11-14	CI
Linical Co., Ltd.(TSE:2183) dropped from S&P Global BMI Index	22-09-19	CI
Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	22-08-12	CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-08-12	CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-05-16	CI
Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 9, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	22-05-16	CI
Linical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022	22-02-14	CI
Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022	22-02-14	CI

Chart Linical Co., Ltd.

Duration

Period

More charts

Company Profile

Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Linical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LINICAL CO., LTD.	-24.72%	57.32M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research